Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Should You Sell?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) gapped down before the market opened on Thursday . The stock had previously closed at $33.55, but opened at $31.71. Nanobiotix shares last traded at $32.2510, with a volume of 8,028 shares changing hands.

Analyst Ratings Changes

A number of research firms have weighed in on NBTX. Leerink Partners lifted their target price on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 4th. UBS Group lifted their target price on Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Guggenheim lifted their target price on Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a report on Monday, May 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.33.

Nanobiotix Stock Performance

The company has a 50 day moving average of $37.63 and a 200-day moving average of $29.41.

Nanobiotix (NASDAQ:NBTX) last issued its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $3.42 million during the quarter. On average, equities analysts expect that Nanobiotix S.A. – Sponsored ADR will post 0.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Nanobiotix

Several hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its stake in Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after purchasing an additional 2,500 shares during the last quarter. Optiver Holding B.V. bought a new stake in Nanobiotix during the third quarter worth about $101,000. Marshall Wace LLP bought a new stake in Nanobiotix during the fourth quarter worth about $220,000. Finally, Millennium Management LLC bought a new stake in Nanobiotix during the fourth quarter worth about $390,000. Institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.